StemCell Therapy

Global Bionic Eye Market: Introduction

According to Encyclopedia Britannica, Inc., bionic eye is an electrical prosthesis, which is surgically implanted into a human eye in order to allow for the transduction of light, i.e. the change of light from the environment into impulses the brain can process in people who have sustained severe damage to the retina. The bionic eye comprises an external camera and transmitter and an internal microchip. The camera is mounted on a pair of eyeglasses, where it serves to organize the visual stimuli of the environment before emitting high-frequency radio waves. In the U.S., the FDA has approved just one commercially available bionic eye system. The device, called the Argus II Retinal Prosthesis System, was developed by a California-based company Second Sight Medical Products. Different bionic eye models take aim at different target areas in the visual pathway. Bionic eye implants work inside the existing eye structure or in the brain. These are designed to achieve functional vision goals as opposed to physical, cosmetic ones.

Read Report Overview - https://www.transparencymarketresearch.com/bionic-eye-market.html

Key Drivers of Global Bionic Eye Market

Rise in Prevalence of Vision Loss

The global population has increased by 18.5% in 2002 over that in 1990. The population 50 years of age and older has increased by nearly 30%. Population increase is more prominent in developing countries. Health is the centerpiece of development and poverty alleviation continuing to eliminate avoidable blindness among the poorest of the poor is a moral imperative. According to The Lancet Global Health, a report estimated that in 2015, 36.0 million people were blind, 217 million had moderate and severe vision impairment, 188 million had mild vision impairment, and 667 million additional people had vision impairment from uncorrected presbyopia.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81541

Rise in Prevalence of Eye Diseases

According to the World Health Organization, globally, at least 2.2 billion people have a vision impairment or blindness, of whom at least 1 billion have a vision impairment that could have been prevented or has yet to be addressed. Tens of millions have a severe vision impairment and could benefit from rehabilitation, which they are not currently receiving. Aging population coupled with rise in sedentary lifestyle and unhealthy eating habits also contribute toward increase in number of people with eye conditions and vision impairment are likely to augment the global market.

Request for Analysis of COVID-19 Impact on Bionic Eye Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81541

North America to Account for Major Share of Global Bionic Eye Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=81541

Key Players Operating in Global Bionic Eye Market

The global bionic eye market is highly consolidated owing to the presence of several key players.

Pre Book Bionic Eye Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=81541&ltype=S

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Go here to see the original:
Bionic Eye Market: Rise in Prevalence of Eye Diseases is expected to drive the market - BioSpace

No one can dispute the value that our eyes hold in our lives. One of the most vital organs, a pair of good healthy eyes can not only help us safely and ably navigate the challenges in our day-to-day life but ensures a lifetime of attainment and self-realization. Conversely, a not-so-healthy pair of eyes can become such a debilitating handicap in our daily routine. While some minor as well as major eye diseases are fairly common and treatable, there are some which continue to pose a challenge to the ophthalmic community. Glaucoma is one of those eye conditions. If timely detection and treatment is not carried out, it can lead to an individual even losing his eyesight. In fact, glaucoma is one of the leading causes of irreversible blindness.

What is Glaucoma?

Glaucoma is a term used to depict a group of diseases which entail a progressive or irreversible damage to the optic nerve of the eye, which if untreated may lead to loss of sight. It is a result of the increased pressure inside the eye which usually happens because of the build-up of a fluid known as aqueous humor in the eye. As this fluid gets obstructed or blocked, the resultant increase in intraocular pressure can damage the optic nerve which in time can weaken the eyesight and eventually lead to complete loss of vision.

Mass screening doesnt help, opportunistic screening important

Unlike Cataract, which can be detected during mass screening of a given population, Glaucoma requires a patient to specifically visit an eye doctor. This visit could be for any eye condition when an opportunistic screening can reveal whether an individual has the dreaded eye condition or not. A comprehensive eye examination with a set of tests such as dilated eye exam (to widen pupils and view optic nerve), slit lamp exam (to view inside of eye), visual acuity test (to check for vision loss), tonometry (to evaluate eye pressure), gonioscopy (to check for eye drainage), pachymetry (to measure corneal thickness), optical coherence tomography (changes in optic nerve), optic nerve head examination (to examine loss of ganglion cells and their fibres), and visual field examination(to check for any peripheral vision loss) would need to be conducted in order to establish whether an individual has glaucoma or not.

Types of Glaucoma

Generally, there are three major types of glaucoma: primary open angle glaucoma (POAG), primary angle closure glaucoma (PACG) and Secondary glaucoma. POAG is the most common type and occurs when the drainage system gets choked and progresses imperceptibly over a long time. Then PACG, a more serious type, is the result of the iris being too close to the drainage canals in the cornea. In this, the eye pressure can rise suddenly due to complete blockage of the drainage angle and unless medically intervened immediately, the individual can lose his eyesight. In a variant called Normal Tension Glaucoma, the optic nerve is damaged without the eye pressure going beyond the average range and is caused by the abnormalities in the blood flow to the optic nerve, and structural weakness of the optic nerve tissue. NTG is not very common. Secondary glaucoma is caused by other diseases which may increase eye pressure leading to optic nerve damage. These include Pigmentary glaucoma, Pseudoexfoliativeglaucoma, traumatic glaucoma, neovascular glaucoma, Irido-Corneal Endothelial Syndrome and Congenital/Childhood glaucoma.

Signs and Symptoms of Glaucoma

Each type of glaucoma has its own signs and symptoms. For instance, POAG has no perceivable or visible symptoms in the early stages and in due course of time as the disease progresses, blind spots develop in the peripheral vision. Similarly, PACG exhibits no apparent symptoms as such and can lead to a sudden attack. Signs of an acute attack would include intense pain in the eye or forehead, foggy vision, redness in the eye, halos around eyes, nausea and vomiting. Again in NTG, blind spots emerge in the field of vision which is a symptom. The symptoms in Secondary glaucoma would depend on the additional disease which is responsible for glaucoma. For Childhood or Congenital glaucoma, a baby would show sensitivity to light and clouding of Cornea. Children are also likely to frequently rub their eyes.

Who are at risk?

Although it can afflict anyone, those with a family history, advanced age or with co-morbidities such as high blood pressure, heart disease or diabetes are more likely to be at risk of getting glaucoma. In addition, those who have been on corticosteroid medications for long, or have undergone certain eye surgeries are also more at risk. Importantly, those with normal eye pressure can also get glaucoma.

Treatment

Again, the line of treatment would depend on the symptoms, stage and type of glaucoma. Typically, there are three major forms of treatment: medication/eye drops, laser treatment and surgery. And often a combination of treatments is also followed. For instance, POAG is most often treated with a combination of eye drops and surgery. But PACG is treated with a laser procedure called iridotomy in which the doctor creates a small opening in your iris using a laser allowing fluid to flow through it, relieving eye pressure. Another laser procedure is called Trabeculoplasty which is used for POAG patients. However in some cases, operating room surgery is opted for. Trabeculectomy is an important surgery in which an opening in the white of the eye (sclera) is created whilea part of the trabecular meshwork is removed by the doctor. You must remember that surgery may require follow-up sessions and a repeat surgery may also not be impossible.For Infants and congenital glaucoma, surgery is the main treatment.

Therefore, glaucoma is aptly called the silent thief of sight. With 12 million people affected and nearly 1.2 million people being blind from the disease in India, mass-level awareness campaigns must be mounted throughout the country. Also, individuals of all age groups must subject themselves to a comprehensive eye examination periodically. Parents should be alert to their babys eye conditions.Because glaucoma simply doesnt give you a second chance.

Views expressed above are the author's own.

END OF ARTICLE

View original post here:
Glaucoma: A leading cause of irreversible blindness - The Times of India Blog

Dr. Marshall Walker will be the guest speaker for Stillwater Medical Foundations First Friday presentation March 5.

Walker is an optometrist whose topic will be Low Vision and Vision Rehabilitation. He is the only board certified low vision specialist in north central Oklahoma. First Friday is still a virtual event, so it will begin its Facebook live stream noon Friday.

1.Can you tell us a little of your background?

I earned his doctorate of optometry with honors from Pennsylvania College of Optometry. I trained at the prestigious Bascom Palmer Eye Institute in Miami, Florida and Feinbloom Low Vision Center in Philadelphia. Afterward, I completed a post-graduate residency in ocular disease and refractive surgery through Northeastern State University Oklahoma College of Optometry. I served as an assistant clinical professor at the Oklahoma College of Optometry and served at Indian Health Service Clinics throughout Northeastern Oklahoma before starting my practice at Stillwater Eyecare.

2. What are some highlights of your discussions?

Gain an understanding of the difference between low vision and blindness. Learn about the most common eye and brain conditions that can vision loss and how to avoid complications. Introduce assistive technologies to education attendees on ways to improve quality of life in individuals suffering vision impairment.

3. Can you give us an example of the kind of therapy involved in low-vision rehabilitation?

Vision rehabilitation is a team approach which includes a low vision specialist, occupational therapists, mental health professionals and social services coordinators. Different therapy recommendations depend on the needs of the individual patient. Specific rehabilitation therapies vary vastly and could be education of how to use a device to read text, or a training someone to navigate their environment with a white cane.

4. Whats a common misconception about eyesight?

Prevention is key. A common misconception about eyesight is a person will notice if they have a problem. There are many potentially blinding conditions that have no perceivable effects until the condition is advanced. This is why yearly comprehensive eye exams are so important.

5. Is there anything youd like us to know?

If someone has sudden vision change or loss, sudden eye pain or a red eye, they should call to be seen as soon as possible.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

See original here:
Q5: First Friday will feature discussion on low vision - Stillwater News Press

The Automotive Recognition System market study provides a comprehensive narrative of the global market landscape and lays out the essentials as well as the other business affecting factors for the client to better understand the market scope and potential. The Automotive Recognition System market report delivers information on various crucial business and market dynamics and anticipates the market growth in the forecast.

Request Sample Copy of the Report @https://www.reportsintellect.com/sample-request/1909489?ata

NOTE: The Automotive Recognition System report has been formulated while considering the COVID-19 Pandemic and its impact on the market.

Key Stakeholders mentioned in this report: CogniVue, EyeSight Technologies, Intel, Qualcomm, Gestsure Technologies, Microsoft

This research study will help you in strengthening the position of your business and organization in the global Automotive Recognition System market landscape. The report will help you to draft strategies that will sustain your business in the long term and give you credible information to implement these strategies in the most effective way possible.

Based on Type Coverage:

Hand/Leg/Finger Print RecognitionFace RecognitionVision/Eye Recognition

Based on Application Coverage:

MultimediaLightingsOthers

Based on Regions and included:

North America(the United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Get a Discount on this report @https://www.reportsintellect.com/discount-request/1909489?ata

Scope:

The Automotive Recognition System market comes up with detailed information related to critical aspects which are essential for a good growth strategy in the market landscape. The market study also profiles the vital players and details their business models.

Highlights of Automotive Recognition System Market Report:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

[emailprotected]Phone No: + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,`Atlanta, GA 30303

Read more here:
Automotive Recognition System Market landscape are detailed in this report for your convenience by: CogniVue, EyeSight Technologies, Intel, Qualcomm,...

Some of the most recognizable traditional sports players in the world wear Oakley. Now, Oakley can add Call of Duty League All-Star Seth Scump Abner to its roster to go alongside other Oakley athletes such as Patrick Mahomes, JuJu Smith-Schuster, Erika Hara, and others. Abner, who currently plays for OpTic Chicago, is now the first-ever esports athlete to sign with the iconic sunglass maker. Abner will be relying on Oakleys first eye-wear solution developed specifically for gaming Prizm Gaming Lens Technology.

Why Oakley? The name speaks for itself. When you hear the word Oakley, you think of a very prestigious brand in the glasses space, Abner told The Esports Observer. I watch a ton of sports. I see Oakley all over the place. My favorite sport to watch is baseball and you see those players wearing them every day. Oakley is just an amazing brand, a very cool, and a very hip brand as well. I think Oakley just kinda speaks for itself.

Oakley, with roots already laid deep inside the traditional sports space, sees esports as another competitive space where players share in the pursuit of progression, giving it everything theyve got. Abner encapsulates that vision as he had had to overcome various vision problems in order to become the player he is today.

I cant see anything. Having glasses that help me see and are comfortable are the two most important things I need in a pair, Abner said. Playing at the highest level, I need to be able to see everything and react to everything perfectly with no discomfort. You dont want to have to worry about things inside of the game because of things outside of the game. These Oakleys are pretty much an attachment of me now.

Abner, who used to wear contacts which he said sometimes itch because of bad allergies, now says he wears glasses again. And the prescription lenses that come with a blue-blocking agent, have helped him tremendously.

I used to wear contacts quite a bit, but now I wear only glasses exclusively, Abner said. So again, its just really important and amazing that Ive found a pair that I really like helps with my eye strain. Its just as cool that the brand is Oakley.

Despite the ailments with allergies and eyesight, Abner has been able to dominate the Call of Duty esports scene. In fact, the two-time Major League Gaming (MLG) X Games gold medalist who was awarded the Best Console Player at the 2017 Esports Industry Awards is often referred to as The King.

Ive been wearing their product for probably two months now, Abner said. The prisms fit perfectly under my Turtle Beachs [headset]. With the Oakleys and the Turtle Beachs, I have no strain on the top of my ears, which after eight hours, you can imagine how much that would hurt. I havent had any issues with these so far and theyre just really comfortable and easy to wear while Im gaming.

However, it wasnt just Abners skill in playing Call of Duty that saw Oakley reach out to him for this partnership, but also his philanthropic endeavors. Abner has grown into a global ambassador for esports by interacting with his fans and followers through various forms of content creation. He has also participated in charity streams and recently took part in a philanthropic campaign to honor those battling COVID-19.

Read more from the original source:
Seth 'Scump' Abner Signed by Oakley as its First Professional Esports Athlete - The Esports Observer

Mrs Beryl Close, from Tonypandy. Image:Freshwater.

Submitted by Freshwater on behalf of Specsavers

A Rhondda man was so concerned about his mother's eyesight and that it was affecting her mental health, that he arranged for an optician home visit during lockdown.

Beryl Close, 75, from Tonypandy in the Rhondda Valley, struggled with her mobility and when her eyesight started worsen during the lockdown. So much so that it began to have a big impact on her life.

Her son, Mike, got in touch with Specsavers, as he was concerned about his mums vision. She couldnt read or see the TV and he was worried that it was affecting her mental health.

During his visit to see Mrs Close, optometrist and director of home visits in Cardiff and the Vale of Glamorgan for Specsavers, Jason Scaife found that she had bad cataracts in both eyes and needed surgery. Cataract removal surgery is a quick procedure, which takes between 15 to 45 minutes, and leaves patients with much brighter and clearer vision.

Having had her surgery at Nuffield Health Hospital in Cardiff Bay to remove the cataracts, Mrs Close has now made a full recovery.

Mr Scaife said: "Her whole demeanour was different after the operation. It became evidently clear that it was her sight problems that were causing her anxiety. She was back to her usual self after the procedure, which was heart-warming to see.

"Beryls story is yet another example of why primary health services cannot stall because of Covid-19. We completely understand why people may be anxious to seek treatment and medical advice while Covid-19 remains prevalent in our communities, which is why our staff both those working remotely as well as colleagues in Specsavers stores have worked hard to ensure we are Covid-secure at all times."

Specsavers staff use personal protective equipment (PPE) while visiting someones home and thoroughly sanitise all equipment and glasses frames between appointments.

Specsavers stores and home visits service in Wales currently remain open for all eye and hearing needs. Specsavers will adhere to each countrys industry guidance if and when changes to local rules are made.To find out more information, request an appointment or browse the online store, visit http://www.specsavers.co.uk/stores.

Read the original post:
Optician's home visit helped save Rhondda woman's deteriorating eyesight - In Your Area

NESS ZIONA, Israel--(BUSINESS WIRE)--Foresight Autonomous Holdings Ltd., an innovator in automotive vision systems (Nasdaq and TASE: FRSX), today reported financial results for the fourth quarter and full year 2020. Foresight ended the fourth quarter of 2020 with $43.9 million in cash and short-term deposits.

Foresight reported a GAAP operating loss of $12.84 million for the full year 2020 which is an approximately 15% less than the GAAP operating loss of $15.03 million reported for the full year 2019. Foresight reported a GAAP net loss of $3.96 million and $15.32 million for the fourth quarter 2020 and the full year, respectively, and a non-GAAP net loss of $3.71 million for the fourth quarter and $14.16 million for the full year 2020.

We achieved important key milestones during the fourth quarter of 2020 and maintained solid progress throughout the year in spite of the COVID-19 pandemic, said Haim Siboni, Foresights CEO. We are entering 2021 with a strong balance sheet, following successful capital raises including $26 million raised in our registered direct offering announced on December 28, 2020. We will continue to build on our innovative product portfolio, which has been validated through key prototype orders and partnerships in Europe, Asia and North America.

The successful year also extends to our subsidiary, Eye-Net Mobile, and our affiliate, Rail Vision. Both companies achieved major business milestones during the fourth quarter of 2020, as Rail Vision received a second investment of $10 million from a leading Tier One European-based group, Knorr-Bremse, in October 2020, and Eye-Net Mobile signed a distribution agreement with Cornes Technologies, a leading Japanese trading house. We believe that Rail Vision and Eye-Net Mobile are poised for further growth in 2021, concluded Mr. Siboni.

Fourth Quarter 2020 Financial Results

Full Year 2020 Financial Results

Full year endedDecember 31,

Three months endedDecember 31,

(thousands of U.S. dollars)

2020

2019

2020

2019

GAAP Results

Net loss

$(15,324)

$(15,439)

$(3,964)

$(4,370)

Non-GAAP Results

Net loss

$(14,162)

$(13,476)

$(3,712)

$(4,018)

Balance Sheet Highlights

Fourth Quarter Corporate Highlights:

Use of Non-GAAP Financial Results

In addition to disclosing financial results calculated in accordance with United States generally accepted accounting principles (GAAP), the company's earnings release contains non-GAAP financial measures of net loss for the period that excludes the effect of share-based compensation expenses, the revaluation of other investments and revaluation of derivative warrant liability, and non-GAAP financial measures of shareholders equity that excludes the effect of derivative warrant liability and the revaluation of other investments. The companys management believes the non-GAAP financial information provided in this release is useful to investors understanding and assessment of the company's ongoing operations. Management also uses both GAAP and non-GAAP information in evaluating and operating business internally and as such deemed it important to provide all this information to investors. The non-GAAP financial measures disclosed by the company should not be considered in isolation or as a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated. Reconciliations between GAAP measures and non-GAAP measures are provided later in this press release.

About Foresight

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing smart multi-spectral vision software solutions and cellular-based applications. Through the companys wholly owned subsidiaries, Foresight Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both in-line-of-sight vision systems and beyond-line-of-sight accident-prevention solutions.

Foresights vision solutions include modules of automatic calibration, sensor fusion and dense 3D point cloud that can be applied to different markets such as automotive, defense, autonomous vehicles and heavy industrial equipment. Eye-Net Mobiles cellular-based solution suite provides real-time pre-collision alerts to enhance road safety and situational awareness for all road users in the urban mobility environment by incorporating cutting-edge AI technology and advanced analytics.

For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit http://www.foresightauto.com, follow @ForesightAuto1 on Twitter, or join Foresight Automotive on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Foresight is using forward-looking statements in this press release when it discusses its belief that it is entering 2021 with a strong balance sheet, that it will continue to build on its innovative product portfolio, which it believes has been validated through key prototype orders and partnerships in Europe, Asia and North America, that it believes that Rail Vision and Eye-Net Mobile are poised for further growth in 2021, Rail Visions expected revenue from Knorr-Bremse, and that Foresight will work with students from the University of Michigan to further develop its automotive vision system designed for Advanced Driver Assistance Systems and autonomous vehicles. Because such statements deal with future events and are based on Foresights current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Foresight could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading Risk Factors in Foresights annual report on Form 20-F filed with the Securities and Exchange Commission (SEC) on March 31, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Foresight undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

FORESIGHT AUTONOMOUS HOLDINGS LTD.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

As ofDecember31, 2020(Unaudited)

As ofDecember31, 2019

ASSETS

Current assets:

Cash and cash equivalents

$

38,772

$

4,827

Short term deposits

Link:
Foresight Announces Fourth Quarter and Full Year 2020 Financial Results - Business Wire

Spinal cord injuries are sustained by hundreds of thousands of people every year, with many patients experiencing a significant and often permanent loss of movement and physical sensation resulting from nerve damage.

Beyond intensive physical rehabilitation programs which can improve outcomes in some cases treatment options are virtually non-existent. But new results from a phase 2 clinical trial offer fresh hope for remedies on the horizon.

In an experimental collaboration by scientists in Japan and the US, 13 patients with spinal cord injuries (SCI)experienced a range of functional improvements in their condition after being treated with an intravenous infusion of their own stem cells, derived from their bone marrow.

The stem cells in question are known as mesenchymal stem cells (MSCs), which are multipotent adult stem cells with the ability to differentiate into a variety of cell types, enabling them to repair bone, cartilage, muscle, or fat tissue.

Despite the potential promise of these cells, their use as an actual therapy has generated considerable controversy, especially after Japan fast-tracked commercialisation approval in late 2018in advance of thorough data on the safety and effectiveness of the experimental treatment.

Over two years later, the researchers behind the therapy, called Stemirac, now have more of those data to share, and while it won't be enough to placate critics, the findings nonetheless offer valuable new information on what MSCs may do for patients with SCI.

"The idea that we may be able to restore function after injury to the brain and spinal cord using the patient's own stem cells has intrigued us for years," explains neurologist Stephen Waxman from Yale University, a senior author of the study .

"Now we have a hint, in humans, that it may be possible."

In the study, the researchers point out that while other trials have also looked at using MSCs to treat SCI via injection methods, their own technique, using intravenous infusion, could have particular benefits.

"Importantly, intravenously infused MSCs may affect not only the injury site, but other parts of the central nervous system including brain and blood vessels," the authors explain in their paper.

Whether that explains some of the results seen in their 13 patients is unclear, but the outcomes themselves are notable.

Of the individuals treated with Stemirac, all of whom had non-penetrative SCIs (meaning their spinal cords were not severed) sustained during serious physical accidents, all but one had demonstrated improvements in key sensory or motor functions by six months after the infusion.

Over half the group showed substantial improvements in things like walking ability or using their hands, and in many cases, graded improvements on a standardised impairment scale could be seen as soon as one day after the treatment, although other cases took weeks.

Significantly, no adverse effects were reported.

While the researchers acknowledge that theirs is a small trial with various limitations including the possibility that the recoveries seen may have been somewhat spontaneous they contend that the initial data show we're looking at something here that's safe, feasible, and worthy of follow-up studies with greater amounts of patients.

"Although this initial case study was unblinded and uncontrolled, the SCI patients appeared to demonstrate a tendency of relatively rapid improvement of neurological function that was often apparent within a few days following infusion of MSCs," the team writes.

As for how the MSC infusion delivers its healing, results from studies on animals have made the researchers think the stem cells secrete neural growth factors that restore important structures that reduce swelling, while restoring vital chemical activity.

In terms of the rapid improvements, the team suggests a chemical called brain derived neurotrophic factor (BDNF) may be involved, which is known to support the health of neurons via numerous mechanisms.

Hopefully, more research in the future can demonstrate the true extent of the potential benefits of this treatment.

The findings are reported in Journal of Clinical Neurology and Neurosurgery.

Visit link:
Controversial Stem Cell Therapy Has Helped Repair Injured Spinal Cords in 13 Patients - ScienceAlert

ASX-listed Cynata Therapeutics has signed an MoU with TekCyte Pty Ltd to access its wound dressing technology in the hope of commercialising TekCytes proprietary surface modifications of polymer-coated dressings for the delivery of Cynatas mesenchymal stem cells, or MSC, to wounds.

The Melbourne-based clinical-stage stem cell and regenerative medicine company is specifically looking to use TekCytes technologies in the commercial development of Cynatas MSC product for the treatment of diabetic foot ulcers.

Cynata said its trademarked Cymerus MSCs have already demonstrated promising efficacy in a pre-clinical model of diabetic wounds, often referred to as diabetic ulcers, utilising TekCytes dressing when seeded with MSCs or similar cells.

The company now plans to build on the solid pre-clinical foundation by conducting a clinical trial of its Cymerus MSC product on patients with diabetic foot ulcers using an active dressing supplied by TekCyte.

Cynata expects to start the clinical trial as soon as possible after it completes negotiations with TekCyte on a formal license agreement.

The company says diabetic foot ulcers are a significant medical problem with an estimated market value of nearly US$10 billion based on data sourced from Transparent Market Researchs review of the global diabetic foot ulcers treatment market out to 2027.

In Australia alone, diabetic foot disease results in more than 27,000 hospitalisations, 4,400 amputations and 1,700 deaths annually. Unfortunately, there is also evidence that the burden of this disease is growing year-on-year, and existing treatment options have limited success.

The very encouraging data from the pre-clinical studies at the CTM-CRC with our Cymerus MSC product, especially when compared with other cell products, provides a rational and sound basis for us to proceed with TekCytes patch technology.

Elsewhere in Cynatas labs and clinical trial sites, the company is working to deploy its stem cell technology across a range of ailments, including Osteoarthritis, renal transplantation, idiopathic pulmonary fibrosis and even COVID-19.

Stem cells, most familiar as embryonic stem cells, are special human cells capable of morphing into all other cell varieties from muscles to brain cells.

Whilst stem cell technology has been developing for a decade or two now, it has been routinely based on using hematopoietic stem cells to treat disease. However, a donor can currently transplant these cells only if a perfect match is available.

Instead of the arduous process of undertaking donor match searches, Cynata believes plentiful stem cells can be derived another way. By transforming adult stem cells with a type of genetic reprogramming, the company says it can create pluripotent stem cells that are capable of operating identically to the valuable embryonic cells.

The companys proprietary Cymerus technology uses pluripotent cells combined with a precursor cell called mesenchymoangioblasts, or MCA to fabricate numerous cell therapy products, including mesenchymal stem cells or MSCs.

Importantly, Cynata says it can produce those essential cells at a commercial scale, forgoing the need for multiple donors and conquering the usual supply bottlenecks currently frustrating stem cell therapies and researchers worldwide.

Other candidate diseases facing this potentially boundless technology include asthma, heart attack, sepsis, acute respiratory distress syndrome, or ARDS and cytokine release syndrome.

Plans are already well advanced for further clinical trials of the fascinating Cymerus MSC products in Graft-versus-host Disease, or GvHD through licensee Fujifilm.

GvHD is an all-too-common consequence of traditional stem cell therapies and is one of the earliest ailments to be attacked by Cynatas technology.

Cynata looks to be hurtling down a path to turn science fiction into reality by developing a wound patch that can effectively regenerate the bodys own cells a bit more than just a band-aid approach, perhaps?

Is your ASX-listed company doing something interesting? Contact: matt.birney@wanews.com.au

Original post:
Cynata tests wound dressing tech for stem cell therapy delivery - The West Australian

Injecting bone marrow stem cells in patients with spinal cord injuries significantly improved their motor functions.

Scientists from Yale University and Sapporo Medical University in Japan reported their findings in the Journal of Clinical Neurology and Neurosurgery on February 18.

The stem cells were prepared from the patients' own bone marrow, and injected intravenously back into the patients, with no side effects from the therapy noted by the researchers. This was not a blind trial, and no placebos were administered.

Over half of the patients reported improved motor functions within weeks of the injections. Key motor functions include walking and using hands.

The patients in question had experienced non-penetrating spinal cord injuries a few weeks prior to the study, which were caused by minor falls or trauma. These injuries left them without motor function or coordination, sensory loss, and bowel and bladder dysfunction.

This type of therapy isn't only ideal for spinal cord injuries, but also for brain injuries, such as strokes. As Jeffery Kocsis of Yale University said "Similar results with stem cells in patients with stroke increases our confidence that this approach may be clinically useful."

Adding to this comment, Stephen Waxman from Yale University said "The idea that we may be able to restore function after injury to the brain and spinal cord using the patients own stem cells has intrigued us for years. Now we have a hint, in humans, that it may be possible."

It's still the early days of this stem cell therapy for spinal cord injuries, and the authors of the study stress that further studies need to be carried out before confirming the results of their initial, unblinded trial something that could take years.

It's still exciting news, as stem cell therapy has been researched for years as a potential remedy for such injuries. Just last year, the Mayo Clinic carried out trials on stem cell therapy for spinal cord injuries. While in Japan, a few eyebrows were raised in 2019 as the nation accepted stem cell therapy to treat spinal cord injuries, perhaps a little prematurely some scientists suggested in the journal Nature.

Continue reading here:
Stem Cell Injections Could Treat Spinal Cord Injuries | IE - Interesting Engineering

Theglobal Canine Arthritis Treatment Marketis expected to reachUS$ 3051.8 Mnby 2028, growing at a moderate CAGR of 4.4%, as per a market intelligence outlook by Future Market Insights, a premier market research firm delivering actionable insights to key leaders across the globe. Mostly found in ageing canines, canine arthritis is a degenerative condition that results in joints inflammation and progresses with time if left untreated. The condition further worsens resulting in associated conditions like osteoarthritis, osteophytosis, and loss of cartilage, in response to pain and inflammation. Injuries, obesity, and poor bone development often leads to canine arthritis.

Rising number of chronic diseases in dogs, globally, is the primary factor driving canine arthritis treatment adoption. Additional factors like increasing number of veterinary clinics couple with stem cell transplants and Non-steroidal anti-inflammatory medications (NSAIDs) are likely to push the market for canine arthritis treatment. Non-steroidal anti-inflammatory medications (NSAIDs) segment is expected to made substantial revenue contribution to overall canine arthritis treatment market followed by opioids during forecast period.

North America, followed byEuropeandAsia Pacific, is expected to be largest consumer of canine arthritis treatment drugs and therapies, owing to existence of developed regulations and superior healthcare infrastructure. For more collaborative research in the canine arthritis market,JapanandSpainare projected to be promising markets.

A sample of this report is available upon request @https://www.futuremarketinsights.com/reports/sample/rep-gb-3552

Use of NSAIDs to Further Shape Canine Arthritis Market

Ease of FDA approval for novel and innovative canine arthritis treatment drugs coupled with growing adoption of canine stem therapy to treat arthritis and huge investments in research and development for the production of NSAIDs and opioids indicated for arthritis especially in European countries is projected to projected to present opportunities to canine arthritis treatment product manufacturers.

The focus presently is on developing high grade NSAIDs, as these drugs are frequently used to manage canines condition-offering a dramatic improvement in mobility and quality of life. The demand for NSAIDs in on a perpetual rise as it lowers the production of prostaglandins-associated with driving inflammation leading to arthritis. In terms of treatment, NSAIDs are continue to be the globally accepted mainstay of pharmaceutical treatment for canine arthritis, further shaping the canine arthritis treatment market. Research suggests that more than 60% of canines above the age of 7, suffer from degenerative joint diseases.

According to a Healthcare Expert at Future Market Insights, Factors such as growing prevalence of chronic diseases in dogs, rising pets adoption, increased consumer spending on veterinary care and fast FDA approvals for drugs used for canine arthritis treatments are expected to boost the global canine arthritis treatment market during the forecast period. Additionally, canine owners opting for canine stem cell therapy over drug medicines is the most lucrative segment in terms of investment opportunities. However, safety issues affecting clinical efficacy of canine pluripotent cells and high therapy costs limit the adoption of canine stem cell therapy. FDA-approved MediVets Autologous Stem Cell and Aratanas Galliprant to control pain and inflammation associated with arthritis, are expected to contribute to the growth of the canine arthritis treatment market.

However, illicit drugs that are falsely registered could restrain the canine treatment market. Such drugs are not manufactured in accordance with regulations, inversely affecting the dogs health coupled with sales of approved drugs. Research shows that counterfeit medicines are more prevalent in under-developed and developing countries. Growing international trade and ecommerce penetrations are fuelling the sales of sub-standard medicine.

Get Access to Research Methodology Prepared by Experts>>>https://www.futuremarketinsights.com/ask-question/rep-gb-3552

Canine Insurances & Direct Drug Sales to Open Canine Arthritis Treatment Opportunities

Pet insurance is an upcoming trend, especially in mature economies. With only 1% dogs insured in the US, the trend is catching up in the region, opening up opportunities for veterinary insurance vendors. However, this number is as high as 50% for pet dogs in some European countries. Moreover, introduction of third-party payers is expected to boost the turnover of the canine arthritis drugs, mostly for the NSAIDs and stem cell therapy segments globally, and lead to build-up of new sales channels for drugs treating canine arthritis.

Also, canine healthcare products manufacturers are relying on direct sales to end-users in a bid to reach out to a larger consumer base. Furthermore, by adopting this sales route, companies are also providing additional training and support in terms of disease management and adherence to treatment protocols.

Key players including Boehringer Ingelheim, Elanco (Eli Lilly and Company), Zoetis Inc., Bayer AG, Aratana Therapeutics Inc., Vetoquinol S.A., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc are developing cost-effective drugs for canine arthritis treatment and increasing sales through acquisitions to enhance their respective market share. Manufacturers are also focusing in developing novel stem cell therapies for treating arthritis. Moreover, companies are focusing partnering with wholesalers, distributors and other channel partners to gain ownership over value chain.

Preview Analysis OnCanine Arthritis Treatment Market Segmentation By treatment type Non-steroidal anti-inflammatory drugs, Opioids, Stem Cell Therapy; route of administration Oral, Injectable:https://www.futuremarketinsights.com/reports/canine-arthritis-market

More from Healthcare, Pharmaceuticals and Medical devices:

Original post:
NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T - PharmiWeb.com

This article was originally published here

Neurol Res. 2021 Feb 25:1-17. doi: 10.1080/01616412.2021.1893564. Online ahead of print.

ABSTRACT

Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of upper and lower motor neurons with high burden on society. Despite tremendous efforts over the last several decades, there is still no definite cure for ALS. Up to now, only two disease-modifying agents, riluzole and edaravone, are approved by U.S. Food and Drug Administration (FDA) for ALS treatment, which only modestly improves survival and disease progression. Major challenging issues to find an effective therapy are heterogeneity in the pathogenesis and genetic variability of ALS. As such, stem cell therapy has been recently a focus of both preclinical and clinical investigations of ALS. This is because stem cells have multifaceted features that can potentially target multiple pathogenic mechanisms in ALS even though its underlying mechanisms are not completely elucidated. Methods & Results: Here, we will have an overview of stem cell therapy in ALS, including their therapeutic mechanisms, the results of recent clinical trials as well as ongoing clinical trials. In addition, we will further discuss complications and limitations of stem cell therapy in ALS. Conclusion: The determination of whether stem cells offer a viable treatment strategy for ALS rests on well-designed and appropriately powered future clinical trials. Randomized, double-blinded, and sham-controlled studies would be valuable.

PMID:33632084 | DOI:10.1080/01616412.2021.1893564

Read the original:
Overview of stem cells therapy in amyotrophic lateral sclerosis - DocWire News

Using a somewhat controversial stem cell therapy, a joint team of Japanese and US-based researchers have successfully repaired some damage in 13 patients with spinal cord injuries (SCI).

SCIs can often cause permanent loss of movement and physical sensation from resultant nerve damage. While physical rehabilitation programs can partially improve outcomes, actual treatment and recovery of lost mobility and function is nigh on impossible. Until now, perhaps.

According to new results from a phase 2 clinical trial conducted in an experimental collaboration by scientists in Japan and the US, patients treated with an intravenous infusion of their own mesenchymal stem cells (MSCs), harvested from their bone marrow, saw significant functional improvements.

MSCs are adult stem cells with the uncanny ability to morph into numerous different cell types, affording them the ability to repair different tissues in the human body, ranging from bone and cartilage to muscle or other tissues.

In 2018, Japan fast-tracked commercial approval of the treatment, opting to forego full testing and regulatory approval despite a lack of complete data on its safety and efficacy. This was much to the consternation of the medical industry at large, and caused considerable controversy in the process.

Fast-forward to the present day and the therapy, called Stemirac, may prove revolutionary in treating non-penetrative SCIs, in which the spinal cord is damaged but remains intact.

In the trials, all 13 patients demonstrated improvements in sensory and motor function six months after they received their infusion, while more than 50 percent of the participants saw substantial improvements in motor function, including walking within a day, though for others it took weeks.

"The idea that we may be able to restore function after injury to the brain and spinal cord using the patient's own stem cells has intrigued us for years," explains neurologist Stephen Waxman from Yale University, a senior author of the study.

"Now we have a hint, in humans, that it may be possible."

Other research has examined the efficacy of injected MSCs to treat SCI, but this new method involves intravenous infusion, which operates in a different way and, so far, has no adverse effects. Still, the researchers acknowledge the limited scope of the trial, as well as the fact that it was unblinded and uncontrolled.

"Importantly, intravenously infused MSCs may affect not only the injury site, but other parts of the central nervous system including brain and blood vessels," the authors explain in their paper.

For now, they suspect the stem cells secrete neural growth factors, particularly brain-derived neurotrophic factor (BDNF), which have a restorative as well as anti-inflammatory effect. While a lot more research is needed to determine the long term safety and efficacy of the treatment, it could one day prove revolutionary.

Think your friends would be interested? Share this story!

More:
We have a hint it may be possible: Controversial stem cell therapy repaired injured spinal cords in 13 patients - RT

Global Stem Cell Therapy Market 2021 Research Report Including Pre COVID-19 and Post COVID-19 Market Scenario

The recent corona crisis (COVID-19) has disrupted national and international Stem Cell Therapy business, adversely affecting the current and future activities of the Stem Cell Therapy industry. It will have a direct and indirect impact on Stem Cell Therapy industry stakeholders and its integrated industries. The significant impact from the COVID-19 lockdown will be on Stem Cell Therapy consumption. Given the current market conditions, the virus is rapidly changing the consumption and supply chain of companies in the market.Global marketers have observed in the latest market intelligence survey that the global Stem Cell Therapy market will record a value of about US $ xx Mn in 2019 and will grow at a CAGR of xx% during the estimated period 2020-2027. In terms of product type, the segment has a significant share of end applications. All Stem Cell Therapy consumption trends and recruitment patterns are listed in the report.

GetFree Sample [emailprotected]https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027#request-sample

Global Stem Cell Therapy Market Key Players:

Segments of the Stem Cell Therapy Report:

Market Segment By Type:

Market Segment By Application

Stem Cell Therapy Market analysis report helps you with intelligent decision-making and better manages the marketing of goods and services leading to business growth. The Stem Cell Therapy Market report looks at the market in terms of general market conditions, industry improvement, market scenario, development, cost and profit in specific market regions, position among key players, and comparative prices. The data and information contained in this Stem Cell Therapy Market business report not only helps businesses make data-driven decisions but also ensures maximum return on investment (ROI).

Do Inquiry Before Purchasing Report Here and Ask For Discount https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027#inquiry-before-buying

The Stem Cell Therapy Industry Report provides in-depth analysis and insights into the developments impacting business and enterprises at the global and regional level. This research report presents a detailed analysis of the key trends, drivers, constraints, and opportunities influencing sales growth. This study focuses on the global Stem Cell Therapy market by share, volume, value, and shape by region along with type and application.

The geographical analysis covers the following regions: North America Europe Asia Pacific Latin America Middle East and Africa

Stem Cell Therapy Market Research provides the following information In-depth analysis of drivers, constraints, opportunities, and trends influencing the growth of the global Stem Cell Therapy market. Important analysis of the Stem Cell Therapy market by product type and end-use industry. Thorough understanding of the strengths, weaknesses, opportunities, and threats of various Stem Cell Therapy market players. Accurate year-on-year growth of the global Stem Cell Therapy market in terms of value and size.

Key questions answered in this report are: What was the global market size in 2019? What is the market size of the different regions and countries around the world? What factors contribute to the development and what are the constraints on development? What types of applications and products are covered in this report? How can market forecasting statistics help the industry growth? What are the potential investment possibilities of the market in other countries/regions?

Browse Detailed Description, TOC, Detailed Segment analysis, Table Of Figures, https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027/#table-of-contents

https://neighborwebsj.com/

Originally posted here:
Global Stem Cell Therapy Market 2021- Regional Analysis(Consumption, Revenue, Market Share and Growth Rate) and Forecast Till 2027 NeighborWebSJ -...

MarketQuest.biz has presented updated research report titled Global Animal Stem Cell Therapy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 which presents vital answers and interpretations concerning market growth and developments in the market. The report contains insightful information like market share, market size, and growth rate, as well as several challenges and ingrained threats and limitations that have interrupted normal growth prognosis in global Animal Stem Cell Therapy market. The report analyzes the segment expected to dominate the industry and market.This market report includes quantitative and qualitative estimation by industry experts, the contribution from industry across the value chain. The report gives information about the supply and demand situation, the competitive scenario, market opportunities, and the threats faced by key players.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Competitive Intelligence:

The leading players are covered in the global Animal Stem Cell Therapy market report with product description, business outline, as well as production, future demand, company profile, product portfolio, product/service price, capacity, sales, and cost. So the entire information related to the company concerning the specific product and in-depth information of collaborations and all other essential information is added in the research report.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/13731

Report has been segmented into geographical segmentation, key players, key topics industry value and demand analysis and forecast and gives comprehensive investigation.The report provides knowledge of the key product segments and their future by having complete insights of market and by making in-depth analysis of market segments. Report includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of global Animal Stem Cell Therapy market.

All top players actively involved in this industry are as follows: Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc, VETSTEM BIOPHARMA, Magellan Stem Cells, J-ARM, Animal Cell Therapies, Celavet Inc., VetCell Therapeutics, Animal Stem Care, Cell Therapy Sciences, Animacel

The report highlights product types which are as follows:Dogs, Horses, Others

The report highlights top applications which are as follows:Veterinary Hospitals, Research Organizations

Promising regions & countries mentioned in the global Animal Stem Cell Therapy market report:North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Market By Manufacturing Cost Analysis:

The study report includes key raw materials analysis, the price trend of key raw materials, key suppliers of raw materials, market concentration rate of raw materials, the proportion of manufacturing cost structure, and manufacturing process analysis. Moreover, the report evaluates the product pricing, production capacity, demand, supply, as well as the historical performance of the global Animal Stem Cell Therapy market.

ACCESS FULL REPORT: https://www.marketquest.biz/report/13731/global-animal-stem-cell-therapy-market-2020-by-manufacturers-type-and-application-forecast-to-2025

Report Offerings:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketquest.biz

Read the original post:
Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU...

Request Download Sample Ask For Discount Company Profile

New Jersey, United States,-The Animal Stem Cell Therapy Market report provides in-depth knowledge and insights into the Animal Stem Cell Therapy market in terms of market size, market share, factors influencing growth, opportunities, and current and emerging trends. The report has the updated and latest information on the Animal Stem Cell Therapy market that has been further validated and verified by industry experts and professionals. The Animal Stem Cell Therapy market report provides historical, current, and forecast estimates of sales generation and profit for each segment and sub-segment of the Animal Stem Cell Therapy market in every key region around the world. The report also highlights the emerging growth opportunities in the business that are designed to support market growth.

The latest report is the latest study to offer 360 coverage of the Animal Stem Cell Therapy industry, which is facing the worst negative economic impact of the COVID-19 outbreak since the beginning of this year.

The report covers the following key players in the Animal Stem Cell Therapy Market:

Medivet Biologics LLC VETSTEM BIOPHARMA J-ARM U.S. Stem Cell Inc VetCell Therapeutics Celavet Inc. Magellan Stem Cells Kintaro Cells Power Animal Stem Care Animal Cell Therapies Cell Therapy Sciences Animacel

Segmentation of Animal Stem Cell Therapy Market:

The report provides an in-depth analysis of various market segments based on the product line, applications, major regions, and key companies in the industry. In addition, the report has a single section that provides a detailed analysis of the manufacturing process and includes information gathered from primary and secondary data collection sources. The main source for data collection is interviews with industry experts who provide accurate information about the future market scenario.

By the product type, the market is primarily split into:

Dogs Horses Others

By the application, this report covers the following segments:

Veterinary Hospitals Research Organizations

Animal Stem Cell Therapy Market Report Scope

Animal Stem Cell Therapy Geographic Market Analysis:

The latest business intelligence report analyzes the Animal Stem Cell Therapy market in terms of market reach and customer base in key geographic market regions. The Animal Stem Cell Therapy market can be geographically divided into North America, Asia Pacific, Europe, Latin America, the Middle East, and Africa. This section of the report provides an accurate assessment of the Animal Stem Cell Therapy market presence in the major regions. It defines the market share, market size, sales, distribution network and distribution channels for each regional segment.

Key Points of theGeographical Analysis:

** Data and information on consumption in each region** The estimated increase in consumption rate** Proposed growth in market share for each region** Geographic contribution to market income** Expected growth rates of the regional markets

Key Highlights of the Animal Stem Cell TherapyMarket Report:

** Analysis of location factors** Raw material procurement strategy** Product mix matrix** Analysis to optimize the supply chain** Patent analysis** R&D analysis** Analysis of the carbon footprint** Price volatility before commodities** Benefit and cost analysis** Assessment and forecast of regional demand** Competitive analysis** Supplier management** Mergers and acquisitions** Technological advances

Visualize Animal Stem Cell Therapy Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website: https://www.verifiedmarketreports.com/

Read the rest here:
Animal Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network - The...

The Stem Cell Therapy Market research report represents a detailed analysis of the future scope, market numbers, revenue, market share, and growth factors for the historic and forecast period 2015-2027. Download a free sample report for a better understanding (Get Free Sample Report)

The Global Stem Cell Therapy Industry Research Report covers 360 degree fundamental market statistics. The competitive structure, market size, market share, revenue analysis and trends are explained in detail in this study. It reflects the product portfolio, specifications, industry plans and policies, and market scope. This is a comprehensive survey that includes a analysis of major player and their market size, share, Business Overview, growth, revenue, compnay profile, Product Profiles, Application and Specification, growth strategies, Market Performance (2015-2020).

This report considers the worlds top players in the industry.

Key PLayers:

This report will help you understand how COVID-19 affected the growth, revenue and more of the Stem Cell Therapy market in 2019-2020 (1st, 2nd, 3rd and 4th quarters). This includes historical and forecast data from 2015 to 2027.

Download Free Sample Including COVID-19 Impact Analysis, TOC, TOF, Charts, Graphs, Detailed Segment Analysis, Key Players Analysis(SWOT & Porters 5 Forces Analysis):https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027/#request-sample

The report begins with a Stem Cell Therapy industry definition and scope that lists product definitions, product types, growth rates, and market size estimates. Market concentration and maturity are taking place in North America, Europe, the Middle East, Africa, Asia Pacific, South America and other regions. The report is segmented based on three key aspects: Stem Cell Therapy type, wide range of product applications, and region. In addition, these top regions are subdivided as follows to provide a country-level analysis of the above regions.

The following section describes import/export details, SWOT analysis, and Stem Cell Therapy industry conditions. Describes a detailed analysis of competitor profiles. The Competitive Profile section displays Stem Cell Therapy market presentations, product details, market value, prices and gross profit for 2019. This report details the Stem Cell Therapy new product launches, mergers and acquisitions, plans and industry policies.

Market Segmentation:

Market By Type:

Market By Application:

Region segment covered

North Americao U.S.o Canada Europeo U.K.o Germanyo Franceo Rest of Europe Asia Pacifico Chinao Japano Indiao Rest of Asia Pacific Latin Americao Brazilo Argentinao Rest of Latin America Middle East and Africao Saudi Arabiao UAEo Turkeyo Rest of Middle East and Africa

Browse Detailed Description, TOC, Detailed Segment analysis, Table Of Figures, https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027/#table-of-contents

Link:
Projected Stem Cell Therapy Market Growth After Coronavirus COVID-19 Outbrek Analysis and Forecast (2020-2027) The Bisouv Network - The Bisouv...

Center for Regenerative Medicine & Stem Cell Therapy at Valencia Medical Center is a pioneer in stem cell regenerative medicine in Santa Clarita Valley has been producing PRP and stem cell treatments for cosmetic treatments for cosmetic rejuvenation, hair restoration and chronic knee pain due to arthritis knee meniscus injury, cartilage, ligaments (ACL, MCL), osteoarthritis treatment.Non-surgical regenerative cell-based treatment uses the bodys natural healing ability to repair damaged bones, muscles, cartilage, tendons and ligaments. Knee injuries are painful and often patients are unable to walk. Our treatment protocol always uses products following FDA guidelines.Injections done with ultrasound guided needle recognition capability to ensure safety as well target the area needing treatment. Plasma; Alpha-2-Macroglobulim (A2M) is the new biologic treatment for your arthritic knee (osteoarthritis)When your hips hurt, or your knee is stiff, or your back is throbbing, that means your joint is bone on bone and there is no lubrication to ease movement.Regenerative medicine giving new hope to patients suffering from painful joint injuries such as knee, shoulder and hip with a chance to live a pain free life.Regenerative cell-based ultrasound guided injection now available to treat pain associated with joint injury. There are indications that it reduces the pain and swelling of the joints and helps lubricating and improve movements.Commonly Treated Conditions: Osteoarthritis of the Hips, Knee, and Shoulders Rotator Cuff tears of the Shoulder Meniscus, ACL and PCL tears of the kneeOur stem cell treatment using your own stem cells and with using imaging guidance ensures precise injection of stem cell, it is a highly-specialized practice.Besides treating above injuries we have advance stem cell micro-needling treatment for the following: Cell-based PRP Hair Restoration combining micro-needling with growth factors and hair follicles voluma vitamins plus BLotinyl T1, Biotin, Anti-aging and Kopexil.Dr. Ibrahim is the staff physician at Valencia Medical Center specializing in regenerative medicine, pain management, and rejuvenation. Call for a consultation at 661-222-9117.

See original here:
Stem Cell and PRP Injection for Knee Osteoporosis Pain and Injury Using US Image Guidance - Magazine of Santa Clarita

The global Animal Stem Cell Therapy market is expected to surge at a steady CAGR in the coming years, states the latest Report Hive Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Animal Stem Cell Therapy market. Analysts have used Porters five forces analysis and SWOT analysis to explain the various elements of the market in absolute detail. Furthermore, it also studies the socio-economic factors, political changes, and environmental norms that are likely to affect the global Animal Stem Cell Therapy market.

The research report is committed to giving its readers an unbiased point of view of the global Animal Stem Cell Therapy market. Thus, along with statistics, it includes opinions and recommendation of market experts. This allows the readers to acquire a holistic view of the global market and the segments therein. The research report includes the study of the market segments on the basis of type, application, and region. This helps in identifying segment-specific drivers, restraints, threats, and opportunities.

The following Companies as the Key Players in the Global Animal Stem Cell Therapy Market Research Report: Key players

MediVet BiologicVETSTEM BIOPHARMAJ-ARMCelavetMagellan Stem CellsU.S. Stem CellCells Power JapanANIMAL CELL THERAPIESAnimal Care StemCell Therapy SciencesVetCell TherapeuticsAnimacelAratana Therapeutics

Request a Sample of this report at:@https://www.reporthive.com/request_sample/2470743

Segmental AnalysisThe report has classified the global Animal Stem Cell Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Animal Stem Cell Therapy manufacturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Animal Stem Cell Therapy industry.

Animal Stem Cell Therapy market by Types:

DogsHorsesOthers

Animal Stem Cell Therapy market by Applications:

Veterinary HospitalsResearch Organizations

Regional Analysis:Besides segmental breakdown, the report is highly structured into region wise study. The regional analysis comprehensively done by the researchers highlights key regions and their dominating countries accounting for substantial revenue share in the Animal Stem Cell Therapy market. The study helps understanding how the market will fare in the respective region, while also mentioning the emerging regions growing with a significant CAGR. The following are the regions covered in this report.

The scope of the Report: The research report on the global Animal Stem Cell Therapy market is a comprehensive publication that aims to identify the financial outlook of the market. For the same reason it offers a detailed understanding of the competitive landscape. It studies some of the leading players, their management styles, their research and development statuses, and their expansion strategies.The report also includes product portfolios and the list of products in the pipeline. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Get Customized PDF template of this report:https://www.reporthive.com/request_customization/2470743

Key questions answered in the report:

About us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

Read more:
Animal Stem Cell Therapy Market Potential Growth, Share and Demand Analysis of Key Players MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet NY...

Request Download Sample Ask For Discount Company Profile

New Jersey, United States,-The Musculoskeletal Disorder Stem Cell Therapy Market report provides in-depth knowledge and insights into the Musculoskeletal Disorder Stem Cell Therapy market in terms of market size, market share, factors influencing growth, opportunities, and current and emerging trends. The report has the updated and latest information on the Musculoskeletal Disorder Stem Cell Therapy market that has been further validated and verified by industry experts and professionals. The Musculoskeletal Disorder Stem Cell Therapy market report provides historical, current, and forecast estimates of sales generation and profit for each segment and sub-segment of the Musculoskeletal Disorder Stem Cell Therapy market in every key region around the world. The report also highlights the emerging growth opportunities in the business that are designed to support market growth.

The latest report is the latest study to offer 360 coverage of the Musculoskeletal Disorder Stem Cell Therapy industry, which is facing the worst negative economic impact of the COVID-19 outbreak since the beginning of this year.

The report covers the following key players in the Musculoskeletal Disorder Stem Cell Therapy Market:

Osiris Therapeutics NuVasive Takeda (TiGenix) Medi-post

Segmentation of Musculoskeletal Disorder Stem Cell Therapy Market:

The report provides an in-depth analysis of various market segments based on the product line, applications, major regions, and key companies in the industry. In addition, the report has a single section that provides a detailed analysis of the manufacturing process and includes information gathered from primary and secondary data collection sources. The main source for data collection is interviews with industry experts who provide accurate information about the future market scenario.

By the product type, the market is primarily split into:

Allogeneic Autologous

By the application, this report covers the following segments:

Muscle disease Skeletal disease

Musculoskeletal Disorder Stem Cell Therapy Market Report Scope

Musculoskeletal Disorder Stem Cell Therapy Geographic Market Analysis:

The latest business intelligence report analyzes the Musculoskeletal Disorder Stem Cell Therapy market in terms of market reach and customer base in key geographic market regions. The Musculoskeletal Disorder Stem Cell Therapy market can be geographically divided into North America, Asia Pacific, Europe, Latin America, the Middle East, and Africa. This section of the report provides an accurate assessment of the Musculoskeletal Disorder Stem Cell Therapy market presence in the major regions. It defines the market share, market size, sales, distribution network and distribution channels for each regional segment.

Key Points of theGeographical Analysis:

** Data and information on consumption in each region** The estimated increase in consumption rate** Proposed growth in market share for each region** Geographic contribution to market income** Expected growth rates of the regional markets

Key Highlights of the Musculoskeletal Disorder Stem Cell TherapyMarket Report:

** Analysis of location factors** Raw material procurement strategy** Product mix matrix** Analysis to optimize the supply chain** Patent analysis** R&D analysis** Analysis of the carbon footprint** Price volatility before commodities** Benefit and cost analysis** Assessment and forecast of regional demand** Competitive analysis** Supplier management** Mergers and acquisitions** Technological advances

Visualize Musculoskeletal Disorder Stem Cell Therapy Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website: https://www.verifiedmarketreports.com/

View original post here:
Musculoskeletal Disorder Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The...